ImmunityBio
IBRX · Nasdaq · United States
Share price · IBRX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when IBRX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 9 Nov 2026-17.7%
- 27 Oct 2026+10.5%
Nothing announced by IBRX that day or the session before.
- 19 Oct 2026-8.3%
- 2 Oct 2026+10.8%
Nothing announced by IBRX that day or the session before.
- 30 Sep 2026+6.9%
Nothing announced by IBRX that day or the session before.
- 22 Sep 2026+9.9%
Nothing announced by IBRX that day or the session before.
- 26 Jun 2026+11.8%
Nothing announced by IBRX that day or the session before.
- 18 Feb 2026+41.9%
- 20 Jan 2026+17.4%
Nothing announced by IBRX that day or the session before.
- 16 Jan 2026+39.7%
Share of unusual movement by asset
For each asset, the share of IBRX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | IL-15 superagonistProtein / enzyme therapeutic | Non-Small Cell Lung CancerBladder CancerPancreatic Cancer | |
| Phase 1 | N/A (innate, non-antigen-specific NK-cell cytotoxicity)Cell therapy | Non-Small Cell Lung Cancer |
Upcoming events
(10 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
November 2026 (1)
What to watch
2027 (4)
2028 (2)
2029 (2)
August 2029 (1)
What to watch
December 2029 (1)
What to watch
2030 (1)
December 2030 (1)
What to watch
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $49M | — | $45M+ $289M short-term inv. | $185M-$75M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | — | —+ $282M short-term inv. | —-$66M operating cash flow | report ↗ |
| 2026-Q1 | $44M | — | $205M+ $176M short-term inv. | $633M-$75M operating cash flow | report ↗ |
| 2025-Q3 | $32M | — | $60M+ $198M short-term inv. | $67M-$69M operating cash flow | report ↗ |
| 2025-Q2 | $26M | — | $138M+ $16M short-term inv. | $93M-$80M operating cash flow | report ↗ |
| 2025-Q1 | $17M | — | $61M+ $0.9M short-term inv. | $130M-$86M operating cash flow | report ↗ |
| 2024-Q3 | $6.1M | $50M | $112M+ $18M short-term inv. | $86M-$99M operating cash flow | report ↗ |
| 2024-Q2 | $1.1M | $51M | $130M+ $88M short-term inv. | $135M-$100M operating cash flow | report ↗ |
| 2024-Q1 | <$0.1M | $53M | $133M+ $37M short-term inv. | $134M-$107M operating cash flow | report ↗ |
| 2023-Q3 | $0.1M | $48M | $178M+ $12M short-term inv. | $96M-$87M operating cash flow | report ↗ |
| 2023-Q2 | <$0.1M | $53M | $44M+ $2.5M short-term inv. | $138M-$80M operating cash flow | report ↗ |
| 2023-Q1 | $0.4M | $79M | $88M+ $2.8M short-term inv. | $116M-$84M operating cash flow | report ↗ |
| 2022-Q3 | $0.1M | $72M | $104M+ $6.9M short-term inv. | $111M-$81M operating cash flow | report ↗ |
| 2022-Q2 | <$0.1M | $63M | $62M+ $21M short-term inv. | $95M-$91M operating cash flow | report ↗ |
| 2022-Q1 | <$0.1M | $55M | $36M+ $156M short-term inv. | $103M-$75M operating cash flow | report ↗ |
| 2021-Q3 | $0.1M | $49M | $65M+ $16M short-term inv. | $88M-$73M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $113M | — | $88M+ $154M short-term inv. | $88M-$305M operating cash flow | report ↗ |
ImmunityBio reported revenue of $113.29M, up 668.1% YoY, cash and equivalents of $88.33M, and a net loss of $351.4M for fiscal year 2025.
Figures only: this period's report disclosed no narrative text
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $15M | $190M | $143M+ $6.4M short-term inv. | $103M-$391M operating cash flow | report ↗ |
| 2023-FY | $0.6M | $232M | $265M+ $1.0M short-term inv. | $146M-$367M operating cash flow | report ↗ |
| 2022-FY | $0.2M | $248M | $105M+ $2.5M short-term inv. | $104M-$338M operating cash flow | report ↗ |
| 2021-FY | $0.9M | $196M | $181M+ $136M short-term inv. | $87M-$274M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 16 sales ($9.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-05 | Simon Barry J. · director | Open-market sale | 25,000 | $10.75 | $269K | Form 4 |
| 2026-10-02 | Cohen Cheryl · director | Option exercise | 55,979 | $2.98 | $167K | Form 4 |
| 2026-10-02 | Cohen Cheryl · director | Open-market sale | 81,056 | $10.50 | $851K | Form 4 |
| 2026-10-02 | Cohen Cheryl · director | Option exercise (derivative) | 55,979 | — | — | Form 4 |
| 2026-07-02 | Cohen Cheryl · director | Option exercise | 55,979 | $2.98 | $167K | Form 4 |
| 2026-07-02 | Cohen Cheryl · director | Open-market sale | 131,210 | $9.50 | $1.2M | Form 4 |
| 2026-07-02 | Cohen Cheryl · director | Option exercise (derivative) | 55,979 | — | — | Form 4 |
| 2026-07-01 | Selecky Christobel · director | Option exercise | 35,064 | $2.98 | $104K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 383 reporting institutions held 177.9M shares ($1.3B, 16.7% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 26,346,443 | $202.1M |
| 2 | STATE STREET CORP | 17,708,103 | $135.8M |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 16,322,844 | $125.2M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 15,127,714 | $116.0M |
| 5 | D. E. Shaw & Co., Inc. | 12,571,597 | $96.4M |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 8,031,921 | $61.6M |
| 7 | TWO SIGMA INVESTMENTS, LP | 4,385,500 | $33.6M |
| 8 | MORGAN STANLEY | 4,018,869 | $30.8M |
| 9 | Woodline Partners LP | 3,447,346 | $26.4M |
| 10 | GOLDMAN SACHS GROUP INC | 3,237,078 | $24.8M |
| 11 | UBS Group AG | 2,944,888 | $22.6M |
| 12 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 2,927,552 | $22.5M |
| 13 | NORTHERN TRUST CORP | 2,504,781 | $19.2M |
| 14 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2,477,941 | $19.0M |
| 15 | BANK OF AMERICA CORP /DE/ | 2,447,843 | $18.8M |